Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health Economics Review
Published in: Health Economics Review 1/2012

Open Access 01-12-2012 | Research

Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model

Authors: Deniz Schobert, Vanessa Remy, Oliver Schoeffski

Published in: Health Economics Review | Issue 1/2012

Login to get access

Abstract

Introduction

Persistent infections with human papillomavirus (HPV) are a necessary cause of cervical cancer and are responsible for important morbidity in men and women. Since 2007, HPV vaccination has been recommended and funded for all girls aged 12 to 17 in Germany. A previously published cost-effectiveness analysis, using a static model, showed that a quadrivalent HPV vaccination programme for 12-year-old girls in Germany would be cost effective. Here we present the results from a dynamic transmission model that can be used to evaluate the impact and cost-effectiveness of different vaccination schemas.

Methods

We adapted a HPV dynamic transmission model, which has been used in other countries, to the German context. The model was used to compare a cervical cancer screening only strategy with a strategy of combining vaccination of females aged 12–17 years old and cervical cancer screening, based on the current recommendations in Germany. In addition, the impact of increasing vaccination coverage in this cohort of females aged 12–17 years old was evaluated in sensitivity analysis.

Results

The results from this analysis show that the current quadrivalent HPV vaccination programme of females ages 12 to 17 in Germany is cost-effective with an ICER of 5,525€/QALY (quality adjusted life year). The incremental cost-effectiveness ratio (ICER) increased to 10,293€/QALY when the vaccine effects on HPV6/11 diseases were excluded. At steady state, the model predicted that vaccinating girls aged 12 to 17 could reduce the number of HPV 6/11/16/18-related cervical cancers by 65% and genital warts among women and men by 70% and 48%, respectively. The impact on HPV-related disease incidence and costs avoided would occur relatively soon after initiating the vaccine programme, with much of the early impact being due to the prevention of HPV6/11-related genital warts.

Conclusions

These results show that the current quadrivalent HPV vaccination and cervical cancer screening programmes in Germany will substantially reduce the incidence of cervical cancer, cervical intraepithelial neoplasia (CIN) and genital warts. The evaluated vaccination strategies were all found to be cost-effective. Future analyses should include more HPV-related diseases.
Appendix
Available only for authorised users
Literature
1.
Baseman JG, Koutsky LA: The epidemiology of human papillomavirus infections. J Clin Virol 2005,32(Suppl 1):S16-S24.PubMedCrossRef
2.
Walboomers JM, Meijer CJ, Steenbergen RD, van Duin M, Helmerhorst TJ, Snijders PJ: Human papillomavirus and the development of cervical cancer: concept of carcinogenesis. Ned Tijdschr Geneeskd 2000, 144: 1671–1674.PubMed
3.
Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14: 1157–1164. 10.1158/1055-9965.EPI-04-0812PubMedCrossRef
4.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121: 621–632. 10.1002/ijc.22527PubMedCrossRef
5.
von Krogh G: Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001, 11: 598–603. quiz 604PubMed
6.
De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124: 1626–1636. 10.1002/ijc.24116PubMedCrossRef
7.
Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14: 467–475. 10.1158/1055-9965.EPI-04-0551PubMedCrossRef
8.
9.
10.
Sroczynski G, Schnell-Inderst P, Muhlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, et al.: Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technology Assessment 2010, 6: 1–13.
11.
Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E: Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis 2010, 10: 360. 10.1186/1471-2334-10-360PubMedCentralPubMedCrossRef
12.
Schenck U, von Karsa L: Cervical cancer screening in Germany. Eur J Cancer 2000, 36: 2221–2226. 10.1016/S0959-8049(00)00313-0PubMedCrossRef
13.
Robert Koch-Institut: Mitteilung der Ständigen Impfkommission (STIKO) in Epidemiologisches Bulletin. 2007, 12: 97–103.
14.
15.
16.
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al.: Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364: 401–411. 10.1056/NEJMoa0909537PubMedCentralPubMedCrossRef
17.
Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al.: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365: 1576–1585. 10.1056/NEJMoa1010971PubMedCrossRef
18.
Hillemanns P, Petry KU, Largeron N, McAllister R, Tolley K, Busch K: Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Pub Health 2009, 17: 77–86. 10.1007/s10389-008-0228-3CrossRef
19.
Dasbach EJ, Largeron N, Elbasha EH: Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoeconomics Outcomes Res 2008, 8: 491–500. 10.1586/14737167.8.5.491CrossRef
20.
Dasbach EJ, Insinga RP, Elbasha EH: The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008, 115: 947–956. 10.1111/j.1471-0528.2008.01743.xPubMedCrossRef
21.
Elbasha EH, Dasbach EJ, Insinga RP: Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13: 28–41. 10.3201/eid1301.060438PubMedCentralPubMedCrossRef
22.
Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM: Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007, 26: 128–139. 10.1016/j.vaccine.2007.10.056PubMedCrossRef
23.
Elbasha EH, Dasbach EJ, Insinga RP: A multi-type HPV transmission model. Bull Math Biol 2008, 70: 2126–2176. 10.1007/s11538-008-9338-xPubMedCrossRef
24.
25.
Beasley M, Williams SG, Pickles T: Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy. Radiat Oncol 2008, 3: 8. 10.1186/1748-717X-3-8PubMedCentralPubMedCrossRef
26.
National survey of sexual attitudes and lifestyles II, 2000–2001 Accessed on 23 January 2012 10.5255/UKDA-SN-5223-1.
27.
Kerek-Bodden H, Altenhofen L, Brenner G: Abschlussbericht. Durchführung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungsdaten, Zentralinstitut für die kassenärztliche. Berlin: Versorgung in der Bundesrepublik Deutschland; 2009.
28.
Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369: 1693–1702. 10.1016/S0140-6736(07)60777-6PubMedCrossRef
29.
Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE: Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008, 14: 244–251. 10.3201/eid1402.070499PubMedCentralPubMedCrossRef
30.
Robert Koch-Institut: Gesellschaft der epidemiologischen Krebsregister (Hrsg.). Ausgabe, RKI, Berlin: Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7; 2010.
31.
Petry KU, Breugelmans JG, Benard S, Lamure E, Littlewood KJ, Hillemanns P: Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol 2008, 29: 345–349.PubMed
32.
33.
Myers E, Green S, Lipkus I: Patient preferences for health states related to HPV infection: visual analogue scales vs. time trade-off elicitation. In Proceedings of the 21st International Papillomavirus Conference. Mexico City; 2004.
34.
Hinzl A, Klaiberg A, Brähler E, König HH: Quality of life questionnaire EQ − 5D: modelling and reference values for the general population [Der Lebensqualitätsfragebogen EQ − 5D: Modelle undNormwerte für die Allgemeinbevölkerung]. PsychotherPsych Med 2006, 56: 42–48. 10.1055/s-2005-867061CrossRef
35.
36.
Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11: 39–44. 10.1016/S1473-3099(10)70225-5PubMedCrossRef
37.
Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK: The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87: 544–547. 10.1136/sextrans-2011-050234PubMedCrossRef
38.
Oliphant J, Perkins N: Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J 2011, 124: 51–58.PubMed
39.
Gross MS, Andres R, Soren K: Human papillomavirus (HPV) vaccination in adolescent girls - have we seen a difference? J Pediatr Adolesc Gynecol 2010, 23: e70-e71. 10.1016/j.jpag.2010.01.022CrossRef
40.
Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377: 2085–2092. 10.1016/S0140-6736(11)60551-5PubMedCrossRef
41.
Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343: d5775-d5775. 10.1136/bmj.d5775PubMedCentralPubMedCrossRef
42.
Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, et al.: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2: 868–878. 10.1158/1940-6207.CAPR-09-0031CrossRef
43.
Sinha P, Logan HL, Mendenhall WM: Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol 2012, 33: 130–136. 10.1016/j.amjoto.2011.02.001PubMedCentralPubMedCrossRef
44.
Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Gorner M, Stanley M, Goon PK: Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol 2011, 268: 1541–1547. 10.1007/s00405-011-1714-8PubMedCrossRef
Metadata
Title
Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model
Authors
Deniz Schobert
Vanessa Remy
Oliver Schoeffski
Publication date
01-12-2012
Publisher
Springer Berlin Heidelberg
Published in
Health Economics Review / Issue 1/2012
Electronic ISSN: 2191-1991
DOI
https://doi.org/10.1186/2191-1991-2-19

Other articles of this Issue 1/2012

Health Economics Review 1/2012 Go to the issue

Research

The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective

Review

Wealth and antenatal care use: implications for maternal health care utilisation in Ghana

Research

Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

Research

Reporting heterogeneity in self-assessed health among elderly Europeans

Research

A modified Kakwani measure for health inequality

Research

Who gets a mammogram amongst European women aged 50-69 years?